Loading organizations...
Key people at Brown Biotechnology Investment Group.
Brown Biotechnology Investment Group is a student-led educational organization based in Providence, Rhode Island, that focuses on healthcare investing at the intersection of biotechnology, medicine, and business. Operating out of Brown University, the group fosters interdisciplinary collaboration among undergraduates from diverse academic backgrounds to analyze emerging healthcare opportunities. The organization evaluates potential investments across the biotechnology, healthcare services, and pharmaceutical sectors while building an alumni network for mentorship and career preparation. The student leadership team includes Co-President Connor McDermott, alongside researchers and analysts such as Elaine and Justine, who focus on clinical innovation and pharmaceutical finance. As a university-affiliated educational initiative rather than a traditional commercial enterprise, specific financial metrics regarding assets under management, funding raised, and portfolio valuation remain undisclosed. The organization's exact founding year and its original founders are not currently publicly disclosed.
The Brown Biotechnology Investment Group (BBIG), now known as the Brown Healthcare Investment Group (BHIG), is a student-run investment club at Brown University focused on healthcare investing. Founded to educate students at the intersection of science, medicine, and finance, it manages a diversified, long-only portfolio of healthcare stocks emphasizing quality science, financial viability, timing, and diversification to achieve stable returns and mitigate risk[1][3][6]. The group's mission is to provide hands-on learning through stock pitches, industry panels, and workshops, while building an ecosystem of mentorship connecting undergraduates with alumni, professors, and peers for careers in healthcare investing[1][3].
Its investment philosophy prioritizes assets with compelling clinical efficacy, favorable tolerability, strong revenue growth, healthy margins, and patent protection, sourcing opportunities via bottom-up research across biotech and broader healthcare sectors like oncology, orphan diseases, and emerging technologies[1][3]. BHIG impacts Brown's startup and investing ecosystem by fostering interdisciplinary collaboration, attracting diverse members, and expanding from biotech to general healthcare for risk mitigation, supported by university funding[1][3].
BBIG was established in 2012 by Joshua Cohen (Brown Biomedical Engineering '14) and Aneesha Mehta (Science and Society '13)[1]. Cohen later co-founded Amylyx Pharmaceuticals, a clinical-stage firm targeting neurodegenerative diseases, while Mehta advanced to healthcare equity research at Fidelity and now invests at Bain Capital Ventures[1]. The group started as a platform for students to explore healthcare investing from financial and strategic angles, hosting educational events open to all backgrounds[1][3].
Between the 2018-2019 and 2019-2020 academic years, it rebranded to Brown Healthcare Investment Group amid membership growth, diversified interests, and Brown University funding, broadening from pure biotech to general healthcare for better portfolio balance[1]. This evolution reflects pivotal moments like expanded collaborations with faculty and organizations, solidifying its role in student-led investing[3].
BHIG rides the wave of healthcare innovation, particularly biotech's shift toward RNA platforms, cell therapies, and solutions for unmet needs in oncology, rare diseases, and neurology—trends accelerated by post-pandemic R&D surges and aging populations[1][2][3]. Timing aligns with rising student interest in healthcare-finance intersections amid volatile markets, where diversification counters biotech bear phases[1][3].
Market forces like university-backed student funds and demand for interdisciplinary talent favor BHIG, influencing Brown's ecosystem by democratizing investing education and pipeline-ing diverse graduates into VC, pharma, and equity research[1][3]. It mirrors broader trends in academic investment clubs professionalizing amid $500K+ AUM peers, preparing talent for firms like Bain Capital Ventures[1][5].
BHIG is poised to deepen its healthcare focus, potentially incorporating AI-driven drug discovery or sustainability metrics as biotech evolves toward precision medicine and ESG integration[2][3]. Expanding alumni networks and university support could scale its portfolio and events, amplifying influence on Brown's entrepreneurship scene.
Trends like therapeutic innovation and market volatility will shape its path, evolving BHIG from educational club to a key talent feeder for healthcare VC—echoing its founding ethos of blending science, medicine, and finance for real-world impact[1][3].
Key people at Brown Biotechnology Investment Group.
